You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Rapid screening tool for antibiotic resistant pathogens
SBC: Resonant Sensors Incorporated Topic: NIAIDDESCRIPTION (provided by applicant): The innovation presented in this proposal is a new class of label-free biochemical sensors with applicability in point of care (POC) medical diagnostics. The goal of the project to develop commercial biochip systems with compelling performance metrics targeted for rapid screening of an array of antibiotic resistant microbials in a clinical setting. The biochips ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Compliant Shape Memory Polymer Device for Meniscal Repair
SBC: MEDSHAPE, INC. Topic: NIAMSDESCRIPTION (provided by applicant): The objective of this project is to develop compliant meniscal repair devices based on shape memory polymers. The repair device will be inserted in a less invasive temporary shape and then triggered to expand into its permanent functional shape. Meniscus repair represents an increasingly common and critical soft-tissue based orthopedic procedure. Approximately ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
HEPylated G-CSF: Drug with Safer, Enhanced Delivery for Neutropenia Treatment
SBC: CAISSON BIOTECH, LLC Topic: NCIDESCRIPTION (provided by applicant): Poly[ethylene glycol] (PEG) polymers are widely used by pharma to enhance the physical, chemical, and/or biological nature of promising drug candidates. The process of adding PEG polymers to drug cargo is termed PEGylation and has resulted in several Billion/year drugs. PEGylation protects the cargo when in the body and prolongs therapeutic action. For patient ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Novel Small Molecules for Treating Kidney Disease
SBC: CRO LABORATORIES, INC. Topic: NIDDKDESCRIPTION: Chronic kidney disease (CKD) is a significant and rapidly growing global health crisis. CKD is associated with cardiovascular disease, hypertension, diabetes, obesity, and aging. It is characterized by gradual loss of renal function with increasing proteinuria (albuminuria), interstitial fibrosis, and glomerulosclerosis. Small increases in urinary protein are associated with markedly ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Advanced GST Proteomics for Early Stage Organ-Specific Toxicity Screening
SBC: OXFORD BIOMEDICAL RESEARCH, INC. Topic: NIEHSDESCRIPTION (provided by applicant): Current biomarkers employed in the detection of organ toxicity are often not sensitive enough to detect the early stages of acute organ damage, i.e. at a stage when reducing or eliminating exposure to a toxin could prevent progression of organ damage or a disease process. By the time current toxicity biomarkers are detected in biological fluids there is already ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
NOVEL HIGH THROUGHPUT PLATFORM FOR SCREENING CYTOCHROME P450 INDUCTION
SBC: ORIGINUS, INC. Topic: NIEHSDESCRIPTION (provided by applicant): Metabolism of administered drugs is determined by expression and activity of drug-metabolizing enzymes, such as cytochrome (CYP) P450 enzymes. These P450s are subject to inhibition and sometimes induction by xenobiotics, leading to possible pharmacokinetic drug-drug interactions between co-administrated drugs. Recognizing the problem, the FDA has issued a Draft ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Field Deployable Vapor Intrusion Monitor
SBC: LYNNTECH INC. Topic: NIEHSDESCRIPTION (provided by applicant): Vapor intrusion is the migration of volatile chemicals from the subsurface into overlying buildings, one of the major causes for a large population exposure to hazardous chemicals. These volatile chemicals are often theresult of buried waste and/or contaminated groundwater that can emit vapors that may migrate through subsurface soils and into indoor air spaces ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Optoacoustic system for monitoring biodistribution of nanoparticles in vivo.
SBC: TOMOWAVE LABORATORIES, INC. Topic: NIEHSDESCRIPTION (provided by applicant): We propose novel application of optoacoustic tomography for non-invasive and quantitative analysis of nanoparticle biodistribution in preclinical research. Novel nanotechnology-based treatments of cancer and other diseases with increased specificity and enhanced therapeutic potential are being actively developed at present. There is a pressing need for low-cost ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
New Reagents for the Synthesis of Phosphorodithioate-Modified 2'-O-Methyl RNAs
SBC: AM BIOTECHNOLOGIES, LLC Topic: NIGMSDESCRIPTION (provided by applicant): Functional RNA molecules such as aptamers, siRNAs, miRNAs, and related compounds have enormous potential as human therapeutics and as tools for elucidating gene regulation in vivo. To reach this potential, such molecules must be highly potent and highly nuclease resistant. Unmodified RNAs typically do not meet these requirements. A variety of chemical modificat ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel assay for the analysis of newly synthesized RNA
SBC: BIOO SCIENTIFIC CORPORATION Topic: NIGMSDESCRIPTION (provided by applicant): While changes in mRNA decay rates account for approximately 50% of the regulation of gene expression in the cell, an assay to accurately and reliably measure mRNA half lives is currently not available. In particular, the deficiency of reliable commercial kits which enable the average biomedical research lab to effectively investigate mRNA decay rates is signifi ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health